FGBweb_BFGBweb_BFGBweb_BFGBweb_B
  • THE FOUNDATION
    • About Us
    • Background
    • Our Mission
    • Contact Us
  • PROGRAMS
    • Fellowships
    • Research
  • NEWS & UPDATES
    • News
    • Press Area
  • VIDEO
English
  • Italiano
✕
Olaparib shows promising results in early breast cancer
09/11/2022
How to select patients with breast and ovarian cancer for the treatment with olaparib
21/11/2022

Talazoparib as monotherapy in advanced breast cancer

Published by Fondazione Gianni Bonadonna at 14/11/2022
Categories
  • Events
  • Uncategorized
Tags

    Metastatic breast cancer that has spread to other parts of the human body as an abstract 3D illustration with tumors in an advanced stage of the disease.

    A phase II trial shows promising results with the PARP ihibitor talazoparib in patients with wild-type BRCA1/2 advanced breast cancer

    PARP inhibitors, including talazoparib and olaparib, are currently approved for the treatment of HER2-negative advanced breast cancer in patients who harbor a genomic BRCA1 and/or BRCA2 (gBRCA1/2) mutation; now a new research, recently published in Nature Cancer, shows benefits with talazoparib in patients with pretreated advanced HER2-negative breast cancer or other solid tumors with mutations in homologous recombination pathway genes other than BRCA1 and BRCA2.

    The open-label phase II Talazoparib Beyond BRCA trial involved 13 patients with advanced breast cancer and 7 with other solid tumors, wild-type for BRCA1 and BRCA2 and with a median of two prior lines of therapy for advanced disease. All enrolled patients were treated with talazoparib monotherapy, 1 mg orally daily; the median time on therapy was 23.8 weeks, which was longer in the breast cancer subgroup compared to the non-breast cancer subgroup. Patients with breast cancer with mutations beyond gBRCA1/2 had a 31% overall response rate (four patients), whereas no objective responses were observed in non-breast tumors; three additional patients had stable disease of ≥6 months (clinical benefit rate, 54%). All patients with germline mutations in PALB2 had treatment-associated tumor regression. Tumor or plasma circulating tumor DNA homologous recombination deficiency scores were correlated with treatment outcomes and were increased in all gPALB2 tumors and a gPALB2-associated mutational signature was associated with tumor response. «The Talazoparib Beyond BRCA trial is a prospective study that identifies the sensitivity of gPALB2 breast cancers to PARP inhibition and highlights the core role of PALB2 in BRCA1- and/or BRCA2-mediated homologous recombination DNA repair in human breast cancers. The results are currently being further evaluated in a multi-institutional study, ‘Talazoparib monotherapy in PALB2 mutation associated advanced breast cancer’; these efforts may confirm a patient population that benefits from targeted therapy to improve patient outcomes and diminish toxicity associated with chemotherapies that are commonly used for these patients», authors conclude.

    Share
    0

    Related posts

    20/03/2023

    Dabrafenib and trametinib in anaplastic advanced thyroid cancer


    Read more
    13/03/2023

    Mediterranean diet could improve efficacy of immunotherapy in advanced melanoma


    Read more
    06/03/2023

    Olaparib in BRCA-mutated, HER-2 negative metastatic breast cancer


    Read more

    Follow us

    LinkedIn | Facebook | Twitter
    • Privacy policy
    • Cookie policy
    © 2021 - Fondazione Gianni Bonadonna
      English
      • Italiano
      • English